Development of dual and selective degraders of cyclin-dependent kinases 4 and 6

Cited by (295)

Items 101–200 of 295

1. Discovery of a Potent, Cooperative, and Selective SOS1 PROTAC ZZ151 with In Vivo Antitumor Efficacy in KRAS-Mutant Cancers
   Zehui Zhou, Guizhen Zhou, Chuan Zhou, Zisheng Fan, Rongrong Cui, Yupeng Li, Rui Li, Yuejiao Gu, Huajie Li, Zhiming Ge et al. · 2023 · Journal of Medicinal Chemistry
2. Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders
   Liqun Chen, Yanke Chen, Chunyan Zhang, Bingyang Jiao, Sheng Liang, Tan Qiong, Hongyu Chai, Weihua Yu, Yongzheng Qian, Hui Yang et al. · 2020 · Journal of Medicinal Chemistry
3. Targeting Protein Kinases Degradation by PROTACs
   Fei Yu, Ming Cai, Liang Shao, Jihong Zhang · 2021 · Frontiers in Chemistry
4. A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents
   Brilliant N. Marak, Jayanta Dowarah, Laldingluaia Khiangte, Ved Prakash Singh · 2020 · European Journal of Medicinal Chemistry
5. Design, Synthesis, and Evaluation of Potent, Selective, and Bioavailable AKT Kinase Degraders
   Xufen Yu, Jia Xu, Ling Xie, Li Wang, Yudao Shen, Kaitlyn M. Cahuzac, Xian Chen, Jing Liu, Ramon E. Parsons, Jian Jun Jin · 2021 · Journal of Medicinal Chemistry
6. Degraders upgraded: the rise of PROTACs in hematological malignancies
   Joshua M. L. Casan, John Francis Seymour · 2024 · Blood
7. How many kinases are druggable? A review of our current understanding
   Brian M. Anderson, Peter Rosston, Han Wee Ong, Mohammad Anwar Hossain, Zachary W. Davis‐Gilbert, David Harold Drewry · 2023 · Biochemical Journal
8. Targeting CDK4/6 for Anticancer Therapy
   Jiating Qi, Zhuqing Ouyang · 2022 · Biomedicines
9. The cyclimids: Degron-inspired cereblon binders for targeted protein degradation
   Saki Ichikawa, N. Connor Payne, Wenqing Xu, Chia‐Fu Chang, Nandini Vallavoju, Spencer Frome, Hope A. Flaxman, Ralph Mazitschek, Christina M. Woo · 2024 · Cell chemical biology
10. CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle–Dependent Degradation of CDK2
    Kristin M. Riching, Marie K. Schwinn, James D. Vasta, Matthew B. Robers, Thomas Machleidt, Marjeta Urh, Danette L. Daniels · 2020 · SLAS DISCOVERY
11. AZD5438-PROTAC: A selective CDK2 degrader that protects against cisplatin- and noise-induced hearing loss
    Santanu Hati, Marisa Zallocchi, Robert A. Hazlitt, Yuju Li, Sarath Vijayakumar, Jaeki Min, Zoran Ranković, Sándor Lovas, Jian Zuo · 2021 · European Journal of Medicinal Chemistry
12. Selectivity through Targeted Protein Degradation (TPD)
    Ariamala Gopalsamy · 2022 · Journal of Medicinal Chemistry
13. Structure-activity relationship study of RSL3-based GPX4 degraders and its potential noncovalent optimization
    Cangxin Zheng, Chao Wang, Dan Sun, Han Wang, Bingru Li, Guoquan Liu, Zhenming Liu, Liangren Zhang, Ping Xu · 2023 · European Journal of Medicinal Chemistry
14. D-Type Cyclins in Development and Disease
    Mostafa Saleban, Erica L. Harris, James A. Poulter · 2023 · Genes
15. The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation
    Tomasz Sobierajski, Joanna Małolepsza, Marta Pichlak, Edyta Gendaszewska‐Darmach, K. M. Błażewska · 2024 · Drug Discovery Today
16. Small-Molecule Approaches to Targeted Protein Degradation
    Tyler B. Faust, Katherine A. Donovan, Hong Yue, Philip P. Chamberlain, Eric S. Fischer · 2020 · Annual Review of Cancer Biology
17. Proteases and Their Modulators in Cancer Therapy: Challenges and Opportunities
    Rao Song, Wenliang Qiao, Jun He, Jiasheng Huang, Youfu Luo, Tao Yang · 2021 · Journal of Medicinal Chemistry
18. Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer
    Lin Ma, Yingying Li, Ruixiang Luo, Yuhan Wang, Jiaqi Cao, Weitao Fu, Bolan Qian, Lei Zheng, Longguang Tang, Xinting Lv et al. · 2023 · Journal of Medicinal Chemistry
19. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery
    Jiayue Xi, Ruyue Zhang, Ke Chen, Lin Yao, Muqiong Li, Ru Jiang, Xiaoye Li, Li Fan · 2022 · Bioorganic Chemistry
20. Development of PROTAC degrader probe of CDK4/6 based on DCAF16
    Chunlan Pu, Yuanyuan Liu, Rui Deng, Qingjia Xu, Shirui Wang, Hongjia Zhang, Dan Luo, Xinyu Ma, Yu Tong, Xinyu Ma et al. · 2023 · Bioorganic Chemistry
21. Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer
    Xufen Yu, Dongxu Li, Jithesh Kottur, Huen Suk Kim, Laura E. Herring, Yao Yu, Ling Xie, Xiaoping Hu, Xian Chen, Ling Cai et al. · 2023 · Journal of Medicinal Chemistry
22. Development of CDK4/6 Inhibitors: A Five Years Update
    Alessandra Ammazzalorso, Mariangela Agamennone, Barbara De Filippis, Marialuigia Fantacuzzi · 2021 · Molecules
23. CDK4/6 nano-PROTAC enhances mitochondria-dependent photodynamic therapy and anti-tumor immunity
    Tianyi Wang, Yaming Zhang, Kang Chen, Yi Huang, Yuwei Liu, Shuting Xu, Weiping Wang · 2023 · Nano Today
24. Induced proximity-based therapeutic modalities
    Elizabeth A. King, Margot Meyers, Daniel K. Nomura · 2025 · Nature Reviews Drug Discovery
25. Identification and selectivity profiling of small-molecule degraders via multi-omics approaches
    Natalie S. Scholes, Cristina Mayor‐Ruiz, Georg E. Winter · 2021 · Cell chemical biology
26. Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase
    Sandeep Rana, Jayapal Reddy Mallareddy, Sarbjit Singh, Lidia Boghean, Amarnath Natarajan · 2021 · Cancers
27. Photocaged Cell-Permeable Ubiquitin Probe for Temporal Profiling of Deubiquitinating Enzymes
    Weijun Gui, Siqi Shen, Zhihao Zhuang · 2020 · Journal of the American Chemical Society
28. PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs
    Marı́a Maneiro, Elena De Vita, Daniel Conole, Cyrille S. Kounde, Qisi Zhang, Edward W. Tate · 2021 · Progress in medicinal chemistry
29. Structurally Specific Z-DNA Proteolysis Targeting Chimera Enables Targeted Degradation of Adenosine Deaminase Acting on RNA 1
    Zhen Wang, Dingpeng Zhang, Xing Qiu, Hiroyuki Inuzuka, Yan Xiong, Jing Liu, Li Chen, He Chen, Ling Xie, H. Ümit Kanıskan et al. · 2024 · Journal of the American Chemical Society
30. Light-Controllable PROTACs for Temporospatial Control of Protein Degradation
    Jing Liu, Yunhua Peng, Wenyi Wei · 2021 · Frontiers in Cell and Developmental Biology
31. Targeting the Ubiquitin System in Glioblastoma
    Nico Scholz, Kathreena Mary Kurian, Florian A. Siebzehnrübl, Julien D. F. Licchesi · 2020 · Frontiers in Oncology
32. PROTAC: targeted drug strategy. Principles and limitations
    O. A. Koroleva, Yu. V. Dutikova, A. V. Trubnikov, Fedor A. Zenov, Ekaterina V. Manasova, Alexander Albertovich Shtil, Aleksander V. Kurkin · 2022 · Russian Chemical Bulletin
33. Degradation strategy of cyclin D1 in cancer cells and the potential clinical application
    Shuyi Chen, Ling Li · 2022 · Frontiers in Oncology
34. Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders
    Vidya Jyothi Alli, Pawan Yadav, V. Suresh, Surender Singh Jadav · 2023 · ACS Omega
35. Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases
    Aublette, Marine C., Harrison, Tom A., Thorpe, Elizabeth J., Gadd, Morgan S. · 2022 · Bioorganic & Medicinal Chemistry Letters
36. Tubulin Resists Degradation by Cereblon-Recruiting PROTACs
    Ivana Gasic, Brian J. Groendyke, Radosław P. Nowak, Jinghua Yuan, Joann Kalabathula, Eric S. Fischer, Nathanael S. Gray, Timothy John Mitchison · 2020 · Cells
37. Multiplexed and reproducible high content screening of live and fixed cells using Dye Drop
    Caitlin E. Mills, Kartik Subramanian, Marc A. Hafner, Mario Niepel, Luca Gerosa, Mirra Chung, Chiara Victor, Benjamin L. Gaudio, Clarence Yapp, Ajit J. Nirmal et al. · 2022 · Nature Communications
38. USP7-Based Deubiquitinase-Targeting Chimeras Stabilize AMPK
    Jing Liu, Xiaoping Hu, Kaixiu Luo, Yan Xiong, Li Chen, Zhen Wang, Hiroyuki Inuzuka, Chao Qian, Xufen Yu, Ling Xie et al. · 2024 · Journal of the American Chemical Society
39. How selective are clinical CDK4/6 inhibitors?
    Denisa Hendrychová, Radek Jorda, Vladimı́r Kryštof · 2020 · Medicinal Research Reviews
40. Small-molecule PROTACs: Novel Agents for Cancer Therapy
    Yichao Wan, Chunxing Yan, Han Jie Gao, Tingting Liu · 2020 · Future Medicinal Chemistry
41. Expanding the reaction toolbox for nanoscale direct-to-biology PROTAC synthesis and biological evaluation
    Rebecca Stevens, Harry J. Shrives, Jenni Cryan, Diana Klimaszewska, Peter Stacey, Glenn A. Burley, John D. Harling, David J. Battersby, Afjal H. Miah · 2024 · RSC Medicinal Chemistry
42. Progress of small molecules for targeted protein degradation: PROTACs and other technologies
    Hongyi Zhao, Minhang Xin, San‐Qi Zhang · 2023 · Drug Development Research
43. Current strategies for improving limitations of proteolysis targeting chimeras
    Chunlan Pu, Shirui Wang, Lei Liu, Zhonghui Feng, Hongjia Zhang, Qianyuan Gong, Yueshan Sun, Yuanbiao Guo, Rui Li · 2022 · Chinese Chemical Letters
44. A comprehensive review of emerging approaches in machine learning for de novo PROTAC design
    Yossra Gharbi, Rocío Mercado · 2024 · Digital Discovery
45. A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts
    Alexey L. Chernobrovkin, Cindy Cázares-Körner, Tomas Friman, Isabel Martín Caballero, Daniele Amadio, Daniel Martinez Molina · 2021 · SLAS DISCOVERY
46. Structure‐Based Design of a Macrocyclic PROTAC
    Andrea Testa, Scott J. Hughes, Xavier Lucas, Jane E. Wright, Alessio Ciulli · 2019 · Angewandte Chemie
47. Indolequinone-Based Hypoxia-Activated Proteolysis Targeting Chimeras Selectively Degrade BRD4 in Hypoxic Cancer Cells
    M. Teresa Serafini, Sophie A. Twigger, George Delfas, Maxim Mallerman, Elliot P. Bailey, Ewen D. D. Calder, Ester M. Hammond, Stuart J. Conway · 2025 · Journal of the American Chemical Society
48. Bifunctional degraders of cyclin dependent kinase 9 (CDK9): Probing the relationship between linker length, properties, and selective protein degradation
    Robert J. Tokarski, Chia Sharpe, Andrew C. Huntsman, Brittney K. Mize, Oluwatosin R. Ayinde, Emily H. Stahl, James R. Lerma, Andrew Reed, Bridget Carmichael, Natarajan Muthusamy et al. · 2023 · European Journal of Medicinal Chemistry
49. Targeting CDKs in cancer therapy: advances in PROTACs and molecular glues
    Hany E. S. Marei, Khaled Bedair, Anwarul Hasan, Layla Al-Mansoori, Alice Gaiba, Andrea Morrione, Carlo Cenciarelli, Antonio Giordano · 2025 · npj Precision Oncology
50. Bispecific Aptamer Chimeras Enable Targeted Protein Degradation on Cell Membranes
    Yanyan Miao, Qianqian Gao, Menghan Mao, Chao Zhang, Liqun Yang, Yang Yang, Da Han · 2021 · Angewandte Chemie
51. Inhibitors and PROTACs of CDK2: challenges and opportunities
    Yangjie Zeng, Xiaodong Ren, Pengyao Jin, Zhida Fan, Mengguang Liu, Yali Zhang, Linzhao Li, Ming Zhuo, Jubo Wang, Zhiyu Li et al. · 2024 · Expert Opinion on Drug Discovery
52. Workflow for E3 Ligase Ligand Validation for PROTAC Development
    Nebojša Miletić, Janik Weckesser, Thorsten Mosler, Rajeshwari Rathore, Marina E. Hoffmann, Paul Gehrtz, Sarah Schlesiger, Ingo Volker Hartung, Nicola Berner, Stephanie Wilhelm et al. · 2025 · ACS Chemical Biology
53. Recent advances in dual PROTACs degrader strategies for disease treatment
    Jianyu Liu, Yanzhuo Liu, Jiao Tang, Qianyuan Gong, Guoyi Yan, Hengrui Fan, Xueping Zhang, Chunlan Pu · 2024 · European Journal of Medicinal Chemistry
54. Selective and Potent Molecular Glue Degraders for NIMA‐Related Kinase 7
    Chen, Lu, Huang, Lu, Wen, Wuqiang, Zeng, Pingping, Wu, Yuanyuan, Han, Qiangqiang, Chen, Xi, Guo, Zhixiang, Yu, Haijun, Lu, Wenchao et al. · 2025 · Angewandte Chemie International Edition
55. Design, Synthesis, and Bioevaluation of Transcriptional Enhanced Assocciated Domain (TEAD) PROTAC Degraders
    Huajie Li, Zhiming Ge, Kexin Lin, Wei He, Qinyu Chu, Mingyue Zheng, Sulin Zhang, Tianfeng Xu · 2024 · ACS Medicinal Chemistry Letters
56. Synthesis and biological evaluation of a tumor-selective degrader of PARP1
    Chunlan Pu, Shirui Wang, Dan Luo, Yuanyuan Liu, Xinyu Ma, Hongjia Zhang, Su Yu, Suke Lan, Qing Huang, Rui Deng et al. · 2022 · Bioorganic & Medicinal Chemistry
57. Emerging approaches to CDK inhibitor development, a structural perspective
    Ian Hope, Jane Endicott, Jessica E. Watt · 2022 · RSC Chemical Biology
58. Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs
    André T. S. Vicente, Sara P. S. P. Moura, Jorge A. R. Salvador · 2025 · Communications Chemistry
59. Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src
    Sudhakar Manda, Na Keum Lee, Dong‐Chan Oh, Jeeyeon Lee · 2020 · Molecules
60. Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer
    Samir H. Barghout · 2020 · Anti-Cancer Agents in Medicinal Chemistry
61. A strategy to assess the cellular activity of E3 ligase components against neo-substrates using electrophilic probes
    Pinch, Benika J., Buckley, Dennis L., Gleim, Scott, Brittain, Scott M., Tandeske, Laura, D'Alessandro, Pier Luca, Hauseman, Zachary J., Lipps, Jennifer, Xu, Lei, Harvey, Edward P. et al. · 2022 · Cell Chemical Biology
62. PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies
    Vishnu Muthuraj Kumarasamy, Zhe Gao, Bosheng Zhao, Baishan Jiang, Seth M. Rubin, Kevin Burgess, Agnieszka Katarzyna Witkiewicz, Erik S. Knudsen · 2023 · British Journal of Cancer
63. Development and therapeutic potential of GSPT1 molecular glue degraders: A medicinal chemistry perspective
    Xiujin Chang, Fangui Qu, Chunxiao Li, Jingtian Zhang, Yanqing Zhang, Yuanyuan Xie, Zhongpeng Fan, Jinlei Bian, Jubo Wang, Zhiyu Li et al. · 2024 · Medicinal Research Reviews
64. Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer
    Donatella Romaniello, Alessandra Morselli, Ilaria Marrocco · 2025 · International Journal of Molecular Sciences
65. Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
    Jing Liu, Yunhua Peng, Hiroyuki Inuzuka, Wenyi Wei · 2022 · Seminars in Cancer Biology
66. Harnessing the Deubiquitinase USP1 for Targeted Protein Stabilization
    Chao Qian, Zhen Wang, Yan Xiong, Dingpeng Zhang, Yue Zhong, Hiroyuki Inuzuka, Yihang Qi, Ling Xie, Xian Chen, Wenyi Wei et al. · 2025 · Journal of the American Chemical Society
67. Development of Degraders of Cyclin-Dependent Kinases 4 and 6 Based on Rational Drug Design
    Huan He, Xingsen Zhang, Jie Wang, Qi Liu, Leihao Zhang, Chen Lu, Yuan Yuan, Zhenjiang Zhao, Honglin Li, Zhuo Chen · 2024 · Journal of Medicinal Chemistry
68. Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity
    Eriko Koide, Mikaela L. Mohardt, Zainab M. Doctor, Annan Yang, Mingfeng Hao, Katherine A. Donovan, Christina C. Kuismi, Alissa J. Nelson, Kathryn Abell, Mike Aguiar et al. · 2023 · ChemBioChem
69. Proteolysis-targeting chimeras in biotherapeutics: Current trends and future applications
    Qiong Li, Li Zhou, Siyuan Qin, Zhao Huang, Bowen Li, Bowen Li, Mei Yang, Edouard Collins Nice, Huili Zhu, Canhua Huang · 2023 · European Journal of Medicinal Chemistry
70. Mutant‐Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug‐Resistant Mutations
    Jaebong Jang, Ciric To, Dries J.H. De Clercq, Eunyoung Park, Charles M. Ponthier, Bo Hee Shin, Mierzhati Mushajiang, Radosław P. Nowak, Eric S. Fischer, Michael J. Eck et al. · 2020 · Angewandte Chemie
71. Redirecting the Neo-Substrate Specificity of Cereblon-Targeting PROTACs to Helios
    Alyssa L. Verano, Inchul You, Katherine A. Donovan, Nada Mageed, Hong Yue, Radosław P. Nowak, Eric S. Fischer, Eric S. Wang, Nathanael S. Gray · 2022 · ACS Chemical Biology
72. Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells
    Yamit Shorer Arbel, Ben‐Zion Katz, Ronen Gabizon, Amit Shraga, Yotam Bronstein, Talia Kamdjou, Anat Globerson Levin, Chava Perry, Irit Mazza Avivi, Nir London et al. · 2021 · Frontiers in Oncology
73. Discovery of Potential Inhibitors of CDK1 by Integrating Pharmacophore-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation Studies, and Evaluation of Their Inhibitory Activity
    Vineeta Teotia, Prakash K. Jha, Madhu Chopra · 2024 · ACS Omega
74. Degraders: The Ultimate Weapon Against Amplified Driver Kinases in Cancer
    Pedro Torres‐Ayuso, John Brognard · 2022 · Molecular Pharmacology
75. Discovery of HyT‐Based Degraders of CDK9‐Cyclin T1 Complex
    Rongkun Lin, Jie Yang, Ting Liu, Mingyu Wang, Chongrong Ke, Cheng Luo, Jin Huo Lin, Jiacheng Li, Hua Lin · 2023 · Chemistry & Biodiversity
76. Novel RAF ‐directed approaches to overcome current clinical limits and block the RAS / RAF node
    Rossella Scardaci, Ewa Berlinska, Pietro Scaparone, Sandra Vietti Michelina, Edoardo Garbo, Silvia Novello, David Santamarı́a, Chiara Ambrogio · 2024 · Molecular Oncology
77. PROteolysis‐Targeting Chimeras (PROTACs) in leukemia: overview and future perspectives
    André T. S. Vicente, Jorge A. R. Salvador · 2024 · MedComm
78. Discovery of Potent and Selective G9a Degraders for the Treatment of Pancreatic Cancer
    Yunkai Shi, Qianqian Shen, Ruikai Long, Yiwen Mao, Shuaihang Tong, Yaxi Yang, Jing Gao, Hu Zhou, Yi Chen, Bing Nan Zhou · 2024 · Journal of Medicinal Chemistry
79. Discovery of PRMT3 Degrader for the Treatment of Acute Leukemia
    Wanyi Zou, Mengna Li, Shili Wan, Jingkun Ma, Linan Lian, Guanghao Luo, Yubo Zhou, Jia Xuan Li, Bing Nan Zhou · 2024 · Advanced Science
80. BMP6 Promotes the Secretion of 17 Beta-Estradiol and Progesterone in Goat Ovarian Granulosa Cells
    Shuaifei Song, Wenfei Ding, Hui Yao, Lei Wang, Bijun Li, Yukun Wang, Xue Tang, Yiyu Zhang, Deli Huang, Dejun Xu et al. · 2022 · Animals
81. Proteolysis-Targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1–3
    Martin Roatsch, Anja Vogelmann, Daniel Herp, Manfred Jung, Christian Adam Olsen · 2020 · ChemRxiv
82. Identification of a Potent and Selective CDK9 Degrader as a Targeted Therapeutic Option for the Treatment of Small-Cell Lung Cancer
    Yubo Wang, Mengmeng Wang, Ma Lan, Yan Zhang, Yue Jiao, Shuxin Zhang, Yijie Yang, Jialu Li, Mingming Wei, Sheng Cao et al. · 2025 · Journal of Medicinal Chemistry
83. Microfluidic fabrication of lipid nanoparticles for co-delivery of siRNA and hydroxychloroquine: An engineered theranostic platform for enhanced breast cancer treatment
    Lu Jun Huang, Wenli Guo, Ting Zhao, Yanru Feng, Yue Li, Qingqing An, Chenxi Li, Yiwei Tian, Huaxing Zhang, Chenming Zhou et al. · 2025 · Chemical Engineering Journal
84. Small-Molecule Degraders of Cyclin-Dependent Kinase Protein: A Review
    Bin Yu, Zekun Du, Yuming Zhang, Zhiyu Li, Jinlei Bian · 2021 · Future Medicinal Chemistry
85. Development of potent and selective degraders of PI5P4Kγ
    Wenzhi Ji, Eric S. Wang, Theresa D. Manz, Jie Jiang, Katherine A. Donovan, Xianmixinuer Abulaiti, Eric S. Fischer, Lewis C. Cantley, Tinghu Zhang, Nathanael S. Gray · 2022 · European Journal of Medicinal Chemistry
86. Between Theory and Practice: Computational/Experimental Integrated Approaches to Understand the Solubility and Lipophilicity of PROTACs
    Andrea Venturi, Stefano Di Bona, Jenny Desantis, Michela Eleuteri, Matteo Bartalucci, Massimo Baroni, Paolo Benedetti, Laura Goracci, Gabriele Cruciani · 2024 · Journal of Medicinal Chemistry
87. Perspectives on the Development of First-in-Class Protein Degraders
    Kalyn M. Rambacher, Matthew F. Calabrese, Masaya Yamaguchi · 2021 · Future Medicinal Chemistry
88. Discovery of small molecule degraders for modulating cell cycle
    Liguo Wang, Zhouli Yang, Guangchen Li, Yongbo Liu, Chao Ai, Yu Rao · 2023 · Frontiers of Medicine
89. Casitas b cell lymphoma‑B (Cbl-b): A new therapeutic avenue for small-molecule immunotherapy
    Xiuqi Hu, Erdong Li, Yangguo Zhou, Qidong You, Zhengyu Jiang · 2024 · Bioorganic & Medicinal Chemistry
90. PROTAC as a novel anti-cancer strategy by targeting aging-related signaling
    Yunhua Peng, Donghua Liu, Daoyuan Huang, Hiroyuki Inuzuka, Jing Liu · 2024 · Seminars in Cancer Biology
91. Targeting the cell-cycle machinery for cancer therapy
    Yunhua Peng, Jiejing Liu, Hiroyuki Inuzuka, Jing Liu, Wenyi Wei · 2025 · Trends in Cell Biology
92. Targeting protein tyrosine phosphatases for CDK6-induced immunotherapy resistance
    Xueliang Gao, Yongxia Wu, Joel M. Chick, Andrea Abbott, Baishan Jiang, Jingxin Wang, Susana Comte‐Walters, Roger H. Johnson, Nathaniel P. Oberholtzer, Michael I. Nishimura et al. · 2023 · Cell Reports
93. Exploitation of Proximity-Mediated Effects in Drug Discovery: An Update of Recent Research Highlights in Perturbing Pathogenic Proteins and Correlated Issues
    Can Zhao, Henian Wang, Wenhu Zhan, Xiaoqing Lv, Xiaodong Ma · 2023 · Journal of Medicinal Chemistry
94. EGFR degraders in non‐small‐cell lung cancer: Breakthrough and unresolved issue
    Jiayi Shen, Liping Chen, Jihu Liu, Anzhi Li, Lüyin Zheng, Sheng Chen, Yongdong Li · 2024 · Chemical Biology & Drug Design
95. Exploiting targeted degradation of cyclins and cyclin-dependent kinases for cancer therapeutics: a review
    Suya Zheng, Ye Chen, Zhipeng Zhu, Nan Li, Chunyu He, H. Phillip Koeffler, Xin Han, Qichun Wei, Liang Xu · 2025 · Journal of Zhejiang University SCIENCE B
96. Hydrophobic tagging: A promising paradigm for targeted protein degradation
    Li-Lan Xin, Hongli Wang, Mao Yang, Zhangxiao Guo, Man Zhu, Terry W. Moore, Chu-Ne Dong, Hai-Bing Zhou · 2025 · Cell Insight
97. DNA-Templated Spatially Controlled Proteolysis Targeting Chimera for Cyclin D1–CDK4/6 Complex Protein Degradation
    Rong Zheng, Abhay Prasad, Deeksha Satyabola, Yang Xu, Subhajit Roy, Yichen Yan, Petr Šulc, Hao Yan · 2025 · Journal of the American Chemical Society
98. Application of proteolysis targeting chimeric (PROTAC) technology in protein regulation and drug development
    Yiting He, Tianzuo Liao, Xuan'er Wang, Qian Hui Xiao, Hongmei Wang, Rui Rochelle He, Chenyu Zhao, Xinmiao Tian, Qinghua Gao, Liying Hao · 2025 · Bioorganic Chemistry
99. FDA-approved kinase inhibitors in PROTAC design, development and synthesis
    Kacper Kossakowski, Alina Cherniienko, Lucjusz Zaprutko, Anna Pawełczyk · 2025 · Journal of Enzyme Inhibition and Medicinal Chemistry
100. PROTAC technology for prostate cancer treatment
     Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, Wenyi Wei · 2025 · Acta Materia Medica